Claims for Patent: 6,410,238

Summary for Patent: 6,410,238

Title:	Box-dependent Myc-interacting protein (Bin1) compositions and uses thereof
Abstract:	The present invention provides Bin1 genomic sequences and proteins encoded thereby. Also provided are compositions and methods utilizing these sequences and proteins in the diagnosis and treatment of cancers and hyperplastic disease states. Further provided are oligonucleotides derived from sequences encoding Bin1, as well as compositions and methods utilizing same for diagnostic and therapeutic purposes.
Inventor(s):	Prendergast; George C. (Bala Cynwyd, PA), Sakamuro; Daitoku (West Lafayette, IN)
Assignee:	The Wistar Institute of Anatomy and Biology (Philadelphia, PA)
Application Number:	09/445,247
Patent Claims:	1. A Bin1 brain-specific nucleic acid sequence selected from the group consisting of: (a) Exon 12A SEQ ID NO: 15, (b) Exon 12B SEQ ID NO: 17, (c) Exon 12C SEQ ID NO: 19, (d) Exon 12D SEQ ID NO: 21, (e) intron sequences of SEQ ID NOS: 7 through 12, (f) a sequence which hybridizes to any of the sequences of (a) through (e) under stringent conditions selected from the group consisting of: i. hybridization at 2.times.SSC at 65.degree. C., followed by a washing in 0.1.times.SSC at 65.degree. C. for an hour; ii. hybridization in 50% formamide, 4.times.SSC at 42.degree. C.; iii. hybridization in 4.times.SSC at 55.degree. C., followed by washing in 0.1.times.SSC at 37.degree. C. for an hour, and iv. hybridization in 50% formamide, 4.times.SSC at 30.degree. C.; and (g) a fragment of any of (a) through (f) comprising at least 15 nucleic acids. 2. A vector comprising a Bin 1 nucleic acid sequence of claim 1 under the control of suitable regulatory sequences. 3. A host cell transformed with a Bin 1 nucleic acid sequence of claim 1. 4. An oligonucleotide probe comprising a Bin 1 nucleic acid sequence of claim 1 and a detectable label which is associated with said sequence. 5. A method of detecting a cancer or hyperplastic disease state associated with a deficiency in normal Bin1 and/or abnormal levels of non-functional Bin1 comprising contacting a biological sample from a patient suspected of having said cancer or disease with a nucleic acid sequence of Exon 12A SEQ ID NO: 15. 6. The method according to claim 5, wherein said cancer is a carcinoma or epithelial cell cancer. 7. The method according to claim 5, wherein said cancer is melanoma. 8. The method according to claim 5, wherein said method further comprises the step of performing a nucleic acid amplification step. 9. The method according to claim 5, wherein said method further comprises the step of performing a nucleic acid hybridization step. 10. The method according to any of claim 6, wherein said cancer is selected from the group consisting of prostate cancer, liver cancer and colorectal cancer.

Details for Patent 6,410,238

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-06-06
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-06-06
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-06-06